Yankees Score with ...
Health Care: Drugs
DepoMed Inc. (DEPO: NASDAQ)
$5.89 0.10 | 1.73%
05/24/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -29.78M | 70.73M | 3.90M | -22.01M |
| Operating Gains/Losses | -64.00K | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -1.14M | -6.21M | -1.41M | -1.26M |
| (Increase) Decrease in Inventories | -2.35M | -3.82M | 995.00K | 283.00K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | -145.00K | 4.22M |
| (Decrease) Increase In Payables | 5.66M | 7.81M | 3.08M | 2.48M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 597.00K | 234.00K | -197.00K |
| (Increase) Decrease In Other Working Capital | -10.36M | -11.71M | -11.49M | 14.85M |
| Other Non-Cash Items | 5.65M | 3.87M | 2.03M | 2.66M |
| Net Cash From Continuing Operations | -30.98M | 57.65M | -2.38M | 1.84M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -30.98M | 57.65M | -2.38M | 1.84M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 105.11M | 133.67M | 72.02M | 149.32M |
| Purchases of Property, Plant & Equipment | -6.88M | -698.00K | -179.00K | -629.00K |
| Acquisitions | -26.44M | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -38.46M | -195.16M | -71.32M | -144.57M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 33.33M | -62.19M | 512.00K | 4.13M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 2.69M | 8.30M | 1.42M | 2.04M |
| Repayment of Long-Term Debt | 0.00 | -2.24M | -3.84M | -3.31M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 2.69M | 6.05M | -2.43M | -1.27M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 5.03M | 1.52M | -4.30M | 4.69M |
Portfolios with DEPO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorEarnings Short Squeeze Play...
- Usertracking
- UserAccelerant
- UserRASHID 1
- UserPortfolio 02
- UserJan Jan Portfolio 1
- Contributor10 Surging Stocks Most at R...
Latest DEPO Headlines from TheStreet
- Short Interest In DepoMed Moves 11% Lower 04.25.13 | 04:04 pm
- Top 10 Trending On StockTwits At The Close (March 4) 03.04.13 | 06:03 pm
- Depomed FDA Panel Live Blog 03.04.13 | 07:03 am
- Biotech Stock Mailbag: Ziopharm, Oncolytics, Sarepta 03.01.13 | 06:03 am
- The Next Big Thing In Biotech: DepoMed
02.28.13 | 09:02 am - Depomed Inc. Stock Upgraded (DEPO) 02.22.13 | 04:02 am
- 5 Stocks Under $10 Triggering Breakouts 02.21.13 | 12:02 pm
- Depomed Bear Case: FDA Panel Will Ding Serada 02.04.13 | 08:02 am
- Stocks Under $5: Stealth Healthcare Play 12.19.12 | 11:12 am
- 2013 FDA Drug Approval Decision Calendar 12.19.12 | 09:12 am
Press Releases for DEPO
- Depomed To Present At UBS Global Healthcare Conference - PR Newswire 05.16.13 | 08:05 am
- Depomed To Report First Quarter Fiscal Year 2013 Financial Results On Wednesday, May 8, 2013 - PR Newswire 05.01.13 | 08:05 am
- Depomed To Present At Roth Capital Partners 25th Annual Growth Stock Conference - PR Newswire 03.13.13 | 04:03 pm
- Depomed Provides Update On SEFELSAâ¿¢ FDA Advisory Committee - PR Newswire 03.04.13 | 01:03 pm
- Trading Of Depomed Common Stock Halted - PR Newswire 03.04.13 | 07:03 am
- Depomed To Present At Cowen And Company Health Care Conference - PR Newswire 02.26.13 | 04:02 pm
- Depomed To Report Fourth Quarter Fiscal Year 2012 Financial Results On Wednesday, February 20, 2013 - PR Newswire 02.13.13 | 04:02 pm
- Depomed Announces Appointment Of Vicente J. Anido, Jr., Ph.D. To Board Of Directors, And Retirement Of Directors Julian N. Stern And Craig R. Smith, M.D. - PR Newswire 02.11.13 | 08:02 am
- EmergingGrowth.com Special Report On RVPlus, Inc., Oil And Gas, And Patents Infringement In Pharmaceuticals - PR Newswire 12.28.12 | 08:12 am
- Depomed Announces Dismissal Of Suit Against Two Gralise ANDA Filers Following Withdrawal Of ANDA And Patent Challenge - PR Newswire 12.26.12 | 04:12 pm
Partner Headlines for DEPO
- FDA Panel Kills Sefelsa, Creates Buying Opportunity In Depomed Stock - Seeking Alpha 03.05.13 | 09:03 am
- Roth Capital's Henry Sees Upcoming FDA Panel For Depomed's Sefelsa As A Coin Flip - Seeking Alpha 03.01.13 | 05:03 pm
- Serada Approval Presents Big Upside To Depomed - Seeking Alpha 01.30.13 | 09:01 am
- 5 Pharmaceutical Companies With Insider Buying During August 14-16 - Seeking Alpha 08.19.12 | 05:08 am
- Sell-Offs PROMPT Buying Opportunity for VF Corp. and 3 More Hot Analyst Alerts - Wall St. Cheat Sheet 06.21.12 | 03:06 am
- New Constructs' Most Attractive Stocks for June - Benzinga 06.04.12 | 09:06 am
- The Zacks Analyst Blog Highlights: Watson Pharmaceuticals, Shire, Depomed, Comcast and Microsoft - Press Releases - Zacks 05.18.12 | 09:05 am
- Company News for February 7, 2012 - Corporate Summary - Zacks 02.07.12 | 10:02 am
- 7 Healthcare Stocks Undervalued By Earnings Growth And Cash Flows - Seeking Alpha 02.03.12 | 07:02 pm
- Depomed Announces FDA Approval of Merck's JANUMET XR That Accesses Depomed Patents Licensed to Merck - Benzinga 02.03.12 | 04:02 pm
